Mutations that reduce the catalytic efficiency or even ablate DHCR7 lead to significant pathology in humans, known as Smith-Lemli-Opitz syndrome (SLOS) (43). This evidence concerns the gene DHCR7 and Smith-Lemli-Opitz syndrome.